Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1989 1
1993 1
1994 1
1995 1
1996 1
1999 1
2000 2
2001 2
2002 1
2003 2
2004 1
2005 2
2006 3
2007 6
2008 11
2009 7
2010 5
2011 14
2012 6
2013 12
2014 5
2015 16
2016 12
2017 13
2018 15
2019 15
2020 13
2021 29
2022 22
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-induced Osteomalacia: A Comprehensive Review.
Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, Pepe J, Cipriani C, Thakker RV. Minisola S, et al. Endocr Rev. 2023 Mar 4;44(2):323-353. doi: 10.1210/endrev/bnac026. Endocr Rev. 2023. PMID: 36327295 Review.
Tumor-induced osteomalacia (TIO) is an ultrarare paraneoplastic syndrome due to overproduction of fibroblast growth factor 23 (FGF23), with profound effects on patient morbidity. ...
Tumor-induced osteomalacia (TIO) is an ultrarare paraneoplastic syndrome due to overproduction of fibroblast growth fac …
Osteomalacia Is Not a Single Disease.
Cianferotti L. Cianferotti L. Int J Mol Sci. 2022 Nov 28;23(23):14896. doi: 10.3390/ijms232314896. Int J Mol Sci. 2022. PMID: 36499221 Free PMC article. Review.
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S. Fukumoto S. J Mol Endocrinol. 2021 Feb;66(2):R57-R65. doi: 10.1530/JME-20-0089. J Mol Endocrinol. 2021. PMID: 33295878 Review.
After the identification of FGF23, several kinds of hypophosphatemic rickets/osteomalacia such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) have been shown to be caused by excessive actions of FGF23. ...
After the identification of FGF23, several kinds of hypophosphatemic rickets/osteomalacia such as X-linked hypophosphatemia (XLH) and tum …
Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.
Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, Clifton-Bligh R, Collins M, Florenzano P, Houillier P, Imanishi Y, Imel EA, Khan AA, Zillikens MC, Fukumoto S. Jan de Beur SM, et al. J Intern Med. 2023 Mar;293(3):309-328. doi: 10.1111/joim.13593. Epub 2022 Dec 13. J Intern Med. 2023. PMID: 36511653 Free PMC article. Review.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). ...
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast …
Burosumab for the Treatment of Tumor-Induced Osteomalacia.
Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Jan de Beur SM, et al. J Bone Miner Res. 2021 Apr;36(4):627-635. doi: 10.1002/jbmr.4233. Epub 2021 Jan 12. J Bone Miner Res. 2021. PMID: 33338281 Free PMC article. Clinical Trial.
Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. ...
Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FG …
Tumor-Induced Osteomalacia.
Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Florenzano P, et al. Calcif Tissue Int. 2021 Jan;108(1):128-142. doi: 10.1007/s00223-020-00691-6. Epub 2020 Jun 5. Calcif Tissue Int. 2021. PMID: 32504138 Review.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral production of fibroblast growth factor 23 (FGF23). ...
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral production of fibroblast growth fa …
Tumor induced osteomalacia.
Filipová L, Lazúrová I. Filipová L, et al. Vnitr Lek. 2021 Winter;67(E-8):19-22. Vnitr Lek. 2021. PMID: 35459330 English.
Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome typically caused by small endocrine tumors that secrete fibroblast growth factor 23(FGF23). ...
Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome typically caused by small endocrine tumors that secr …
Tumor-induced osteomalacia.
Chong WH, Molinolo AA, Chen CC, Collins MT. Chong WH, et al. Endocr Relat Cancer. 2011 Jun 8;18(3):R53-77. doi: 10.1530/ERC-11-0006. Print 2011 Jun. Endocr Relat Cancer. 2011. PMID: 21490240 Free PMC article. Review.
Tumor-induced osteomalacia (TIO) is a rare and fascinating paraneoplastic syndrome in which patients present with bone pain, fractures, and muscle weakness. ...
Tumor-induced osteomalacia (TIO) is a rare and fascinating paraneoplastic syndrome in which patients present with bone …
Phosphaturic Mesenchymal Tumor.
Benson JC, Trejo-Lopez JA, Nassiri AM, Eschbacher K, Link MJ, Driscoll CL, Tiegs RD, Sfeir J, DeLone DR. Benson JC, et al. AJNR Am J Neuroradiol. 2022 Jun;43(6):817-822. doi: 10.3174/ajnr.A7513. Epub 2022 May 19. AJNR Am J Neuroradiol. 2022. PMID: 35589138 Free PMC article.
Phosphaturic mesenchymal tumors (PMTs) are neoplasms associated with tumor-induced osteomalacia. Patients typically present with pathologic fractures in the setting of chronic hypophosphatemic hyperphosphaturic osteomalacia, as well as gradual muscle weakness …
Phosphaturic mesenchymal tumors (PMTs) are neoplasms associated with tumor-induced osteomalacia. Patients typically pre …
Diagnosis and management of tumor-induced osteomalacia: a single center experience.
Hacisahinogullari H, Tekin S, Tanrikulu S, Saribeyliler G, Yalin GY, Bilgic B, Isik EG, Salduz A, Tuncer S, Gul N, Uzum AK, Aral F, Tanakol R, Selcukbiricik OS. Hacisahinogullari H, et al. Endocrine. 2023 Nov;82(2):427-434. doi: 10.1007/s12020-023-03450-3. Epub 2023 Jul 22. Endocrine. 2023. PMID: 37480497
PURPOSE: The aim of this study is to review the clinical and laboratory characteristics, diagnostic and treatment modalities of tumor-induced osteomalacia (TIO) cases managed in a single center. ...
PURPOSE: The aim of this study is to review the clinical and laboratory characteristics, diagnostic and treatment modalities of tumor …
225 results